Bone Mineral Density Remains Stable in Pyruvate Kinase Deficiency Patients Receiving Long-Term Treatment with Mitapivat
Hanny Al‐Samkari(Harvard University), Eduard J. van Beers(Utrecht University), Liz Grekas(Agios Pharmaceuticals (United States)), Rachael F. Grace(Dana-Farber/Boston Children's Cancer and Blood Disorders Center), Wilma Barcellini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), John B. Porter(Royal London Hospital), Oliver Andrés(University of Würzburg), Kevin H.M. Kuo(University Health Network), Sarah Gheuens(Biogen (United States)), Marta Morado(Hospital Universitario La Paz), Frederic Galactéros(Inserm), Vip Viprakasit(Siriraj Hospital), Bryan McGee(Agios Pharmaceuticals (United States)), Andreas Glenthoej(Herlev Hospital), Feng Tai(Agios Pharmaceuticals (United States)), Karishma Khoja(Agios Pharmaceuticals (United States)), D. Mark Layton(Imperial College Healthcare NHS Trust), Yan Dong(Tulane University)
Cited by 3
Related Papers
Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study
|Neuromuscular Disorders|2019|636
Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients
|Blood|2014|373
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
|New England Journal of Medicine|2020|320
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia
|New England Journal of Medicine|2022|309